Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia. Innocrin's investors include Novartis Venture Fund, Eshelman Ventures, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings, and Astellas Venture Management.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/15/15 | $28,000,000 | Series D |
A&B Equity Holdings Eshelman Ventures Hatteras Venture Partners Intersouth Partners Novartis Venture Funds | undisclosed |
